Comparing Treatments for Childhood Malaria in Gabon
Author Information
Author(s): Nsimba Basile, Guiyedi Vincent, Mabika-Mamfoumbi Modeste, Mourou-Mbina Jean Romain, Ngoungou Edgard, Bouyou-Akotet Marielle, Loembet Romaric, Durand Rémy, Le Bras Jacques, Kombila Maryvonne
Primary Institution: National Malaria Control Programme – Division for Disease Control, Ministry of Health, Brazzaville, Congo
Hypothesis
Is sulphadoxine/pyrimethamine more effective than amodiaquine for treating uncomplicated childhood malaria?
Conclusion
Sulphadoxine/pyrimethamine is significantly more effective than amodiaquine in treating uncomplicated childhood malaria.
Supporting Evidence
- SP had a day-28 PCR-adjusted treatment failure rate of 11.6%.
- AQ had a day-28 PCR-adjusted treatment failure rate of 28.2%.
- Both treatments were safe and well-tolerated with no serious adverse reactions.
- The dhps K540E mutation was not found in the SP group.
Takeaway
This study found that one medicine works better than another for treating malaria in kids. The better medicine is called sulphadoxine/pyrimethamine.
Methodology
A randomized trial comparing the efficacy of amodiaquine and sulphadoxine/pyrimethamine in children under five with uncomplicated malaria, using a 28-day WHO therapeutic efficacy test.
Limitations
The study was limited to a specific region in Gabon and may not represent the entire country.
Participant Demographics
Children under five years of age with uncomplicated falciparum malaria.
Statistical Information
P-Value
0.019
Confidence Interval
95% CI: 5.5–22.1 for SP; 95% CI: 17.7–38.7 for AQ
Statistical Significance
p=0.019
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website